This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and discusses the implementation of the Affordable Care Act.
This segment from the show focuses on Anacor's (NASDAQ:ANAC) 28% surge after it announced that it will get $100 million from an arbitration ruling against drugmaker Valeant Pharmaceuticals (NYSE:VRX). Analysts David Williamson and Max Macaluso discuss the impact of this ruling on both stocks in the following video.
Incredible growth stock to watch
Alison Southwick has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.